Insider Transactions in Q3 2025 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.99%
|
$530,000
$53.17 P/Share
|
|
Jul 16
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.97%
|
$190,000
$19.87 P/Share
|
|
Jul 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.76%
|
$1,530,000
$51.15 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.34%
|
$637,500
$51.85 P/Share
|
|
Jul 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.51%
|
$262,500
$21.09 P/Share
|
|
Jul 01
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
2,000
-6.27%
|
$104,000
$52.88 P/Share
|